Cyclofem/Cyclo-Provera: emerging countries' perspective.
Cyclo-Provera, the original name of the combination of 25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate, later known as Cyclofem and hereafter referred to MPA/E2C, has proven its use-effectiveness (pregnancy rate less than 1%) in routine service delivery conditions. Overall, the life-table discontinuation rates at 1 year ranged from 33.5% to 71.8%. Only a third of total discontinuations were attributable to the injectable contraceptive method, thus raising the importance of service delivery issues related to its continued use. The results of introductory trials in Mexico, Indonesia, Thailand, Tunisia, Jamaica and, more recently, Brazil, Colombia, Chile and Peru have demonstrated that MPA/E2C is a highly effective contraceptive that could be offered as an alternative to current fertility regulation methods for many women around the world. In addition, the results of studies were the basis for the approval of MPA/E2C by local health authorities and its inclusion in the Ministries of Health Family Planning Programs.
Garza-Flores
J
J
Department of Reproductive Biology, National Institute of Nutrition, Salvador Zubirán, México City, Mexico.
D003271:Contraceptive Agents, Female / Q000009:adverse effects / Q000737:chemistry; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects / Q000737:chemistry; D003692:Delayed-Action Preparations; D003906:Developing Countries; D004338:Drug Combinations; D004958:Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry; D005193:Family Planning Services / Q000379:methods; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D007273:Injections, Intramuscular; D015993:Life Tables; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects / Q000737:chemistry; D010342:Patient Acceptance of Health Care / Q000523:psychology / Q000706:statistics & numerical data; D011247:Pregnancy / Q000706:statistics & numerical data; D011446:Prospective Studies; D012959:Socioeconomic Factors
D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D004958:Estradiol; C034528:CycloProvera; D017258:Medroxyprogesterone Acetate